Circulating tumor markers in breast cancer: Accepted utilities and novel prospects
- 1 November 1998
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 52 (1-3) , 239-259
- https://doi.org/10.1023/a:1006137619153
Abstract
Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor...Keywords
This publication has 74 references indexed in Scilit:
- Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinomaBritish Journal of Cancer, 1997
- Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patientsBritish Journal of Cancer, 1997
- Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3British Journal of Cancer, 1996
- Prostate-specific antigen in serum of women with breast cancerBritish Journal of Cancer, 1995
- Absence of p53 autoantibodies in a significant proportion of breast cancer patientsBritish Journal of Cancer, 1995
- The relationship between serum p53 autoantibodies and characteristics of human breast cancerBritish Journal of Cancer, 1994
- Circulating and Tissue Markers in the Longitudinal Management of Breast Cancer PatientsPublished by Springer Nature ,1994
- Clinical Cancer MarkersPublished by Springer Nature ,1992
- Cancer Markers of the 1990sPublished by Springer Nature ,1992
- Screening for Breast CancerAnnals of Internal Medicine, 1989